Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 1/2 3Phase 2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 2Gynecologic 2Genitourinary 2Dermatologic 2Thoracic 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 15lenvatinib 12atezolizumab 10Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × X-Rays × Clear all
NCT06811116 2026-05-13

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

National Cancer Institute (NCI)

Phase 1/2 Recruiting
92 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡